Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma

The survival benefit of metastasectomy (MSX) in patients with metastatic renal cell carcinoma (mRCC) remains unclear. A reliable model to predict an individuals’ risk of cancer-specific mortality (CSM) and to identify optimal candidates for MSX is needed. We identified 2,911 mRCC patients who underw...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kan, Liu, Zhihong, Shao, Yanxiang, Li, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793951/
https://www.ncbi.nlm.nih.gov/pubmed/33425741
http://dx.doi.org/10.3389/fonc.2020.592243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793951/
https://www.ncbi.nlm.nih.gov/pubmed/33425741
http://dx.doi.org/10.3389/fonc.2020.592243

Ejemplares similares